[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"inoperable\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:inoperable":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":5},"100503310","whole-course-immunonutrition-combined-with-chemoradiotherapyicis-for-local-advanced-patients-with-inoperable-esophageal-squamous-cell-carcinoma-100503310",false,"NCT05833594","Whole-course Immunonutrition Combined With Chemoradiotherapy±ICIs for Local Advanced Patients With Inoperable Esophageal Squamous Cell Carcinoma","Anhui Provincial Hospita","Inclusion Criteria:\n\n* 18-85 years old;\n* Eastern Cooperative Oncology Group (ECOG) 0-2;\n* Esophageal squamous cell carcinoma;\n* cT2-4aN0-3M0 (AJCC 8th) confirmed by radiological examination;\n* initial unresectable at initial diagnosis confirmed by thoracic surgeons;\n* Treatment naive;\n* No contraindications for adjuvant chemoradiotherapy;\n* Signature of inform consent.\n\nExclusion Criteria:\n\n* younger than 18 years old or older than 85 years old;\n* ECOG\\>2;\n* Esophageal adenocarcinoma, small-cell cancer and other pathological types;\n* cT1anyNM0, cT4banyNM0, c anyTanyNM0 confirmed by radiological examination;\n* Resectable at initial diagnosis confirmed by thoracic surgeons;\n* Previous treatment of chemotherapy, radiotherapy, and other treatment;\n* Contraindications for chemoradiotherapy;\n* No signature of inform consent.","ALL","18 Years","85 Years",{"count":20,"type":21},70,"ESTIMATED","OBSERVATIONAL","Chemoradiotherapy has been a standard modality for inoperable locally advance esophageal carcinoma. The goal of this randomized control study is to compare the feasibility, and survival benefits of whole-course immunonutrition combined with chemoradiotherapy±ICIs for local advanced patients with inoperable esophageal squamous cell carcinoma. The main questions it aims to answer are: • If the feasibility and safety of whole-course immunonutrition combined with chemoradiotherapy±ICIs is better. • If the survival benefits (1, 2 and 3-years progression free survival) of whole-course immunonutrition combined with chemoradiotherapy±ICIs is longer. The Experimental group will receive a combination immunonutrition of omega-3 fatty acids, and glutamine, whereas the control group will receive standard formula.",[25,26,27,28],"Esophageal Squamous Cell Carcinoma","Chemoradiotherapy","Immunonutrition","Inoperable","RECRUITING","2023-12-20",{"date":32,"type":33},"2023-12-26","ACTUAL",{"date":35,"type":33},"2023-07-01",{"date":37,"type":21},"2026-12-01",{"name":39,"class":40},"Anhui Provincial Hospital","OTHER_GOV"]